Literature DB >> 27325297

Prevention of breast cancer by RANKL/RANK blockade.

Lorenzo Galluzzi1,2,3,4,5, Aitziber Buqué1,2,3,4,5, Guido Kroemer2,3,4,5,6,7,8.   

Abstract

Robust genetic evidence in mice and humans indicates that RANK signaling plays a major role in mammary carcinogenesis driven by BRCA1/BRCA2 mutations. These findings may inaugurate a new era of breast cancer prevention, changing the life of millions of women worldwide.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27325297      PMCID： PMC5129887          DOI： 10.1038/cr.2016.79

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  10 in total

1.  Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.

Authors:  H Gilbert Welch; David H Gorski; Peter C Albertsen
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

2.  The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

Authors:  J E Fata; Y Y Kong; J Li; T Sasaki; J Irie-Sasaki; R A Moorehead; R Elliott; S Scully; E B Voura; D L Lacey; W J Boyle; R Khokha; J M Penninger
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

3.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Authors:  Daniel Schramek; Andreas Leibbrandt; Verena Sigl; Lukas Kenner; John A Pospisilik; Heather J Lee; Reiko Hanada; Purna A Joshi; Antonios Aliprantis; Laurie Glimcher; Manolis Pasparakis; Rama Khokha; Christopher J Ormandy; Martin Widschwendter; Georg Schett; Josef M Penninger
Journal:  Nature       Date:  2010-09-29       Impact factor: 49.962

Review 4.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

5.  Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.

Authors:  Aleksandra Jovanovic Poole; Ying Li; Yoon Kim; Suh-Chin J Lin; Wen-Hwa Lee; Eva Y-H P Lee
Journal:  Science       Date:  2006-12-01       Impact factor: 47.728

6.  Progesterone/RANKL is a major regulatory axis in the human breast.

Authors:  Tamara Tanos; George Sflomos; Pablo C Echeverria; Ayyakkannu Ayyanan; Maria Gutierrez; Jean-Francois Delaloye; Wassim Raffoul; Maryse Fiche; William Dougall; Pascal Schneider; Ozden Yalcin-Ozuysal; Cathrin Brisken
Journal:  Sci Transl Med       Date:  2013-04-24       Impact factor: 17.956

Review 7.  Natural and therapy-induced immunosurveillance in breast cancer.

Authors:  Guido Kroemer; Laura Senovilla; Lorenzo Galluzzi; Fabrice André; Laurence Zitvogel
Journal:  Nat Med       Date:  2015-10       Impact factor: 53.440

Review 8.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

Review 9.  Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

10.  RANKL/RANK control Brca1 mutation- .

Authors:  Verena Sigl; Kwadwo Owusu-Boaitey; Purna A Joshi; Anoop Kavirayani; Gerald Wirnsberger; Maria Novatchkova; Ivona Kozieradzki; Daniel Schramek; Nnamdi Edokobi; Jerome Hersl; Aishia Sampson; Ashley Odai-Afotey; Conxi Lazaro; Eva Gonzalez-Suarez; Miguel A Pujana; For Cimba; Holger Heyn; Enrique Vidal; Jennifer Cruickshank; Hal Berman; Renu Sarao; Melita Ticevic; Iris Uribesalgo; Luigi Tortola; Shuan Rao; Yen Tan; Georg Pfeiler; Eva Yhp Lee; Zsuzsanna Bago-Horvath; Lukas Kenner; Helmuth Popper; Christian Singer; Rama Khokha; Laundette P Jones; Josef M Penninger
Journal:  Cell Res       Date:  2016-05-31       Impact factor: 25.617
  10 in total
  2 in total

1.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

2.  BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Authors:  Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Oncotarget       Date:  2017-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.